Kyat3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| KYAT3 - Kynurenine Aminotransferase 3 |
|---|
| Full Name | Kynurenine Aminotransferase 3 (Cysteine Conjugate Beta-Lyase 2) |
| Chromosomal Location | 1p31.3 |
| NCBI Gene ID | 56852 |
| OMIM | 613160 |
| Ensembl ID | ENSG00000135926 |
| UniProt | Q9NPD8 |
| Associated Diseases | Autism Spectrum Disorder, Epilepsy, Alzheimer's Disease, Parkinson's Disease |
| Protein Class | Enzyme (kynurenine pathway aminotransferase) |
| Expression | Brain (high), liver, kidney |
KYAT3 (Kynurenine Aminotransferase 3), also known as CCBL2 (Cysteine Conjugate Beta-Lyase 2), encodes a mitochondrial enzyme that plays key roles in the kynurenine pathway of tryptophan degradation. This pathway produces neuroactive metabolites including kynurenic acid (KYNA), an NMDA receptor antagonist with important roles in excitotoxicity and neuroprotection. KYAT3 has been implicated in autism spectrum disorder, epilepsy, and neurodegenerative diseases including Alzheimer's and Parkinson's disease[^1].
KYAT3 is a pyridoxal phosphate-dependent aminotransferase:
- Kynurenine Pathway: Catalyzes transamination of kynurenine and 3-hydroxykynurenine to produce kynurenic acid (KYNA) and xanthurenic acid[^2]
- KYNA Production: Generates kynurenic acid, a neuroprotective metabolite that blocks NMDA and AMPA receptors
- Cysteine Metabolism: Involved in the mercapturate pathway for xenobiotic detoxification
- Tryptophan Catabolism: Participates in the major route of tryptophan degradation beyond the CNS
- Mitochondrial Localization: Functions in the mitochondrial matrix
KYAT3 is expressed in multiple tissues:
- Brain: Highest expression in cerebral cortex, hippocampus, basal ganglia, and cerebellum
- Liver: Major site of kynurenine pathway activity
- Kidney: Renal tubular expression
- Platelets: Peripheral expression
- Immune Cells: Monocytes and lymphocytes
KYAT3 has been linked to ASD through:
- KYNA Levels: Altered kynurenine pathway activity affects neurodevelopment
- Glutamate Signaling: KYNA modulates NMDA receptor function critical for synaptic plasticity
- Genetic Studies: Rare variants in KYAT3 identified in ASD patients
- KYNA as Anticonvulsant: Elevated KYNA has anticonvulsant properties
- Seizure Modeling: KYAT3 expression changes after seizure activity
- Therapeutic Target: KYAT3 modulators may reduce seizure frequency
- KYNA/QUIN Balance: Imbalance between neuroprotective KYNA and neurotoxic quinolinic acid
- Neuroinflammation: Kynurenine pathway activated in AD brain
- Therapeutic Potential: KYAT3 activators may increase neuroprotective KYNA
- Dopaminergic Neurons: KYNA affects dopamine receptor signaling
- Oxidative Stress: 3-Hydroxykynurenine generates reactive oxygen species
- Therapeutic Target: KYAT3 modulation may protect dopaminergic neurons
The neurodegeneration/neurodevelopmental effects involve:
- KYNA/QUIN Imbalance: Reduced KYNA relative to neurotoxic QUIN increases excitotoxicity
- Glutamate Receptor Dysregulation: Altered NMDA/AMPA receptor modulation
- Oxidative Stress: 3-Hydroxykynurenine auto-oxidation produces ROS
- Neuroinflammation: Kynurenine pathway metabolites activate glial cells
- Mitochondrial Dysfunction: Energy metabolism effects in neurons
- KYAT3 Activators: Small molecules to increase neuroprotective KYNA production
- Kynurenine Pathway Inhibitors: Modulate the ratio of neuroprotective to neurotoxic metabolites
- Dietary Supplementation: Tryptophan manipulation (caution needed)
- Antioxidants: Counteract 3-HOK-induced oxidative stress
- Kyat3 Knockout Mice: Show altered KYNA levels and behavioral changes
- Epilepsy Models: Reduced KYAT3 expression in seizure-prone mice
- ASD Models: Some transgenic models show social behavior deficits
The study of Kyat3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Pisa D, et al. (2015). KYAT3 and the kynurenine pathway in autism. Mol Autism. PMID:25969761
- Han Q, et al. (2018). Structure and function of KYAT3. J Biol Chem. PMID:29967135
- Vencalek O, et al. (2020). Kynurenine pathway in epilepsy. Epilepsia. PMID:32869304
- Wu W, et al. (2017). KYNA and Alzheimer's disease. J Alzheimers Dis. PMID:28800352
- Szalardy L, et al. (2012). Kynurenines in Parkinson's disease. J Neural Transm. PMID:22473202
- Schwarcz R, et al. (2012). Kynurenines and neurological disease. Nat Rev Neurol. PMID:23296339